Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Psychoneuroendocrinology. 2011 Feb 8;36(7):1070–1079. doi: 10.1016/j.psyneuen.2011.01.005

Table 1.

Baseline Measures of Metabolic Risk Factors, by Condition and Sex

Active Drug Condition
Placebo Condition
n=42 men, 39 women n=37 men, 41 women
Waist Circumference (cm)
  Men 98.7 (11.9)1 99.6 (13.1)2
  Women 96.0 (14.3)3 91.7 (17.5)3
HDL cholesterol
  Men 41.6 (9.4) 43.1 (8.2)4
  Women 51.2 (10.1) 53.4 (12.1)
Triglycerides
  Men 152.4 (108.1) 150.6 (98.4)
  Women 144.4 (145.9) 116.9 (67.2)
Glucose
  Men 96.5 (12.2) 95.3 (7.9)
  Women 93.4 (13.0) 92.3 (10.9)
Insulin
  Men 15.9 (14.3) 12.8 (6.7)
  Women 17.4 (17.8) 14.1 (9.5)
Blood Pressure (Manual)
  SBP
    Men 109.3 (8.0) 110.9 (9.2)
    Women 106.4 (9.2) 106.4 (8.9)
  DBP
    Men 75.9 (6.1) 77.3 (8.8)
    Women 74.1 (8.3) 74.7 (7.5)
Blood Pressure (Automated)
  SBP
    Men 116.9 (8.6)5 116.0 (9.9)
    Women 107.8 (11.7) 109.4 (12.7)
  DBP
    Men 74.9 (6.3)5 73.8 (7.5)
    Women 70.1 (8.3) 70.7 (7.8)
BMI (kg/m2)
  Men 29.2 (5.0) 28.9 (4.2)
  Women 31.1 (5.6) 28.9 (7.3)
Insulin Resistance (HOMA-IR)
  Men 4.04 (4.60) 3.08 ((1.80)
  Women 4.16 (4.79) 3.27 (2.43)

Note. Scores are displayed as M (std).

1

n=39,

2

n=33,

3

n=35,

4

n=36,

5

n=41.

Note. HOMA-IR=serum insulin (uIU/mL)xfasting blood glucose (mmol/L)/22.5.

HHS Vulnerability Disclosure